PROGNOSTIC PARAMETERS IN SUPERFICIAL BLADDER-CANCER - AN ANALYSIS OF 315 CASES

PROGNOSTIC PARAMETERS IN SUPERFICIAL BLADDER-CANCER - AN ANALYSIS OF 315 CASES
复制标题

DOI:
10.1016/s0022-5347(17)53725-8
复制
发表时间:
1982-01-01
期刊:
影响因子:
6.6
通讯作者:
DAHM, H
DAHM, H
中科院分区:
医学1区
文献类型:
--
作者:
LUTZEYER, W;RUBBEN, H;DAHM, H

文献摘要

被引文献

相似文献

本文报告了一项对315例浅表性移行细胞癌(Ta至T2期)患者进行3年或更长时间随访的回顾性研究。80%的患者进行了经尿道切除术; 20%的患者进行了开放切除或切除术以治愈或控制。除了分级和分期,多灶性肿瘤生长以及肿瘤是原发性还是复发性明显影响复发和肿瘤进展的频率。Ta、T1和T2期肿瘤切除后3年内的总复发率为60%。45%的患者在原发性肿瘤后复发,84%的患者在第二次复发后复发,其中46例发生孤立性肿瘤,73%发生多灶性肿瘤。在24%的孤立性肿瘤患者、44%的多灶性肿瘤患者、20 - 25%的原发和复发Ta期和原发T1期肿瘤患者以及56%的复发T1期肿瘤患者中观察到肿瘤进展。因此,在计划治疗时,应考虑肿瘤的分期、分级、多灶性生长以及肿瘤是原发性还是复发性。Ta期肿瘤即使有几次复发,经尿道切除也能充分治疗。当多灶性或复发性T1或T2期肿瘤复发为浸润性癌时,应考虑更积极的治疗。
A retrospective study of 315 patients with superficial transitional cell carcinoma (stages Ta to T2) and an adequate followup of 3 yr or longer is reported. Transurethral resection was done in 80% of the patients; open excision or resection was done in 20% for cure or control. In addition to grade and stage, multifocal tumor growth and whether the tumor is primary or recurrent evidently influence the frequency of recurrences and tumor progression. The over-all recurrence rate after resection of stages Ta, T1 and T2 tumors within 3 yr was 60%. Recurrences after a primary tumor were noted in 45% of the patients and were followed by a 2nd recurrence in 84%, with solitary tumors occurring in 46 and multifocal tumors in 73%. Tumor progression was observed in 24% of patients with solitary tumors, 44% of those with multifocal tumors, 20-25% of those with primary and recurrent stage Ta and primary stage T1 tumors, and 56% of those with recurrent stage T1 tumors. Therefore, when therapy is planned, stage, grade, multifocal tumor growth and whether the tumor is primary or recurrent should be considered. Stage Ta tumors can be treated sufficiently by transurethral resection even in the case of several recurrences. More aggressive therapy should be considered when multifocal or recurrent stage T1 or T2 tumors recur as invasive carcinomas.